European Commission Publishes New Documents Supporting Monitoring of Medical Device Availability in the EU Market (3 July 2026)

Core Content

On 3 July 2026, the European Commission's Directorate-General for Health and Food Safety (DG SANTE) published new documents relating to the study supporting the monitoring of the availability of medical devices on the EU market. The documents comprise the 20th notified body survey and the 3rd economic operator survey.

This update is closely related to the implementation of Regulation (EU) 2017/745 (MDR) and Regulation (EU) 2017/746 (IVDR), notified body capacity, and the stability of medical device supply in the European Union.

Source and Applicability Note

• Source organisation: European Commission, Medical Devices (Directorate-General for Health and Food Safety)
• Date of original publication: 3 July 2026
• Original source: https://health.ec.europa.eu/latest-updates/new-documents-study-supporting-monitoring-availability-medical-devices-eu-market-2026-07-03_en

This article has been compiled and edited from publicly available information published by the European Commission's Directorate-General for Health and Food Safety. Specific requirements remain subject to the latest official publications of the relevant regulatory authorities.

Translated Core Text

European Commission publishes new documents: study supporting the monitoring of the availability of medical devices on the EU market.

On 3 July 2026, the European Commission's Directorate-General for Health and Food Safety published a news update concerning new documents related to the study supporting the monitoring of the availability of medical devices on the EU market.

According to the European Commission's public page, the update is a news announcement published on 3 July 2026 by the Directorate-General for Health and Food Safety. The page lists two related documents: the 20th notified body survey and the 3rd economic operator survey.

Survey documents of this type are typically used to track feedback from notified bodies, manufacturers, authorised representatives, importers, distributors and other relevant parties on medical device market availability, certification capacity, regulatory transition and accessibility in the context of MDR and IVDR implementation.

The information on the page indicates that the European Commission continues to monitor the availability and supply stability of medical devices on the EU market. For companies preparing to enter the EU market or already holding CE certificates, these documents help to clarify regulatory transition, notified body resources and market supply risks.

This translation has been prepared from the main content of the European Commission's public page. Site navigation, language selection, footer links and non-substantive information have been removed. The link to the original text is retained in the source note above.

AIMEILI Regulatory Interpretation

The publication should not be treated simply as general industry news. When the European Commission's Medical Devices unit issues an update of this kind, companies should first determine whether it concerns regulatory policy, guidance or standards, recalls or safety information, product performance, quality systems, or post-market surveillance. Each category has a different impact on registration pathways, technical documentation, labelling and instructions for use, risk management and ongoing market maintenance.

The release of documents relating to the medical device availability monitoring study has significant strategic reference value for Chinese medical device companies. It shows that EU regulators continue to observe how MDR and IVDR implementation affects notified body capacity, certificate transition, product supply and the responsibilities of economic operators. CE certification should not be understood merely as obtaining a certificate for an individual product; notified body resources, technical documentation queue times, certificate maintenance and supply stability should be built into long-term planning.

Registration Pathway Considerations

From a registration pathway perspective, EU registration under the MDR and IVDR frameworks is clearly different from the former MDD/IVDD era. Notified body reviews are more in-depth, technical documentation evidence chains must be more complete, and requirements for clinical evaluation, performance evaluation, PMS, PMCF/PMPF, PSUR and UDI are more systematic. Companies that do not plan ahead on documentation quality and notified body communication are likely to encounter delays during queuing, deficiency response and certificate transition.

Market Access Considerations

From a market access perspective, the EU's focus on the availability of medical devices shows that regulators are not only examining compliance documentation but also whether regulatory implementation affects patients' and healthcare institutions' access to products. For Chinese companies, this means that registration strategy must consider both compliance and business continuity: which products should be transitioned to the MDR/IVDR first, which products require additional clinical or performance evidence, and which products may exit the EU market due to cost and insufficient evidence should all be decided in advance.

Quality System and Documentation Reuse

From a quality system and documentation reuse perspective, companies should reassess whether existing CE technical documentation can continue to satisfy notified body review. This applies particularly to projects involving multiple models, multiple specifications, multiple manufacturing sites or multiple authorised representatives, where any inconsistency in certificate scope, manufacturing address, label language, UDI, PMS plan or clinical evaluation updates may affect the continuity of EU sales.

Business Impact

For companies preparing for EU registration or maintaining CE certificates, AIMEILI recommends establishing an EU project management table that sets out product risk class, applicable regulation, notified body status, certificate validity, technical documentation maturity, clinical or performance evidence gaps, labelling and UDI readiness, PMS/PSUR plans and key submission milestones. This helps avoid a reactive approach when certificates approach expiry, and is particularly relevant for companies with multiple product lines, multiple models and simultaneous sales in multiple countries.

In practical execution, companies should also break the information down into a checkable task list:

• Regulatory affairs team: confirm whether the target country has taken comparable regulatory action.
• Quality team: confirm whether there are related complaints or adverse events.
• R&D team: confirm whether performance verification and design inputs remain adequate.
• Clinical or medical team: confirm whether there are risks relating to the interpretation of results and the intended use scenarios.
• Marketing and distributor teams: confirm that customer communication materials are accurate and consistent.

For projects under application or about to be submitted, these assessments should be documented in writing and used as supporting material for subsequent deficiency responses, changes, renewals or customer audits.

Where companies use the same product platform to enter multiple GHWP member states, particular attention should be paid to the boundaries of documentation reuse. The same risk management report, performance verification report or instructions for use may require different supplementary explanations under different regulatory systems. AIMEILI recommends that companies do not wait for a regulator to raise questions before supplementing documentation, but instead proactively complete a focused gap assessment once official information is available. This reduces post-market compliance risk and improves the stability of subsequent international registration projects.

FAQ

Can the documents published by the European Commission on 3 July 2026 concerning the medical device market availability monitoring study be used directly as a basis for submission?

No. This article is intended for preliminary understanding and project assessment. Formal submissions must be based on the latest requirements of the target country's regulatory authority, the product classification conclusion and the company's actual documentation status.

What should companies do first after seeing this type of update?

A documentation gap assessment should be carried out first to determine whether the update affects the registration pathway, technical documentation, labelling, quality system or post-market maintenance.